Summary
Background Elevated proinflammatory cytokines have been associated with 2019 coronavirus disease (COVID-19) severity. We assessed efficacy and safety of sarilumab, an interleukin-6 receptor inhibitor, in severe (requiring supplemental oxygen by nasal canula or face mask) or critical (requiring greater supplemental oxygen, mechanical ventilation, or extracorporeal support) COVID-19.
Methods This was a 60-day, randomised, double-blind, placebo-controlled, multinational trial in patients hospitalised with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pneumonia, who required oxygen supplementation or intensive care. Patients were randomised 2:2:1 to intravenous sarilumab 400 mg, sarilumab 200 mg, or placebo. The primary endpoint was time to ≥2-point clinical improvement (7-point scale; range: 1 [death] to 7 [not hospitalised]). The key secondary endpoint was proportion of patients alive at day 29. Safety outcomes included adverse events and laboratory assessments. This trial is registered with ClinicalTrials.gov (NCT04327388).
Findings Between March 28 and July 3, 2020, 420 patients were randomised; 416 received treatment (placebo, n=84; sarilumab 200 mg, n=159; sarilumab 400 mg, n=173). At day 29, there were no significant differences in median (95% CI) time to ≥2-point improvement between placebo (12·0 [9·0–15·0] days) and sarilumab groups (200 mg: 10·0 [9·0–12·0] days, p=0.96, log-rank test; 400 mg: 10·0 [9·0–13·0] days, p=0.34) or in proportions of patients alive (placebo, 91·7%; sarilumab 200 mg, 89·9%, p=0·63; sarilumab 400 mg, 91·9%, p=0·85). At day 29, there were numerical, nonsignificant survival differences between sarilumab 400 mg (88%) and placebo (79%; difference +9%, 95% CI −7·7 to 25·5, p=0·25) for critical patients. There were no unexpected safety signals.
Interpretation This trial did not demonstrate efficacy of sarilumab in patients hospitalised with COVID-19 and receiving supplemental oxygen. Adequately powered trials of targeted immunomodulatory therapies assessing survival as a primary endpoint are suggested in patients with critical COVID-19.
Funding Sanofi and Regeneron Pharmaceuticals, Inc.
Competing Interest Statement
F-XL has received lecture fees from Merck Sharp & Dohme and Gilead Science. HH has nothing to disclose of relevance to this study. RF has no financial conflicts to disclose. JSL, GS, PW, NP, and OH are employees of Sanofi and may hold stock and/or stock options in the company.
Clinical Trial
NCT04327388
Funding Statement
This study was funded by Sanofi (Paris, France) and Regeneron Pharmaceuticals, Inc. (Tarrytown, USA). Special thanks to Meng Zhang, Christine Xu, and Evelyne Dombrecht of Sanofi for their expertise, dedication, and leadership of a remarkable team, and to the members of the IDMC (Kevin Winthrop MD, MPH; Victor Ortega MD, PhD, ATSF; Mitchell Levy MD, Steve Dahlberg MS) and the independent Statistical Data Analysis Center (Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison) for their diligence and equipoise under extraordinary circumstances. This study was funded by Sanofi (Paris, France) and Regeneron Pharmaceuticals, Inc. (Tarrytown, USA). Medical writing assistance was provided by Richard J. Hogan, PhD, and Vojislav Pejovic, PhD, of Eloquent Scientific Solutions, a division of Envision Pharma Group, and editorial and graphics assistance was provided by Eloquent Scientific Solutions. This support was funded by Sanofi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial was monitored by an external independent data monitoring committee (IDMC) with ongoing access to unblinded clinical data. The protocol was approved by the institutional review boards (IRBs) at each participating hospital and by national ethics committees, as required by local and national regulations. The study was carried out in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the World Medical Association's Declaration of Helsinki and its amendments. The list of local and national IRBs and IECs which approved the trial, by center type and country, is shown below, in the following format: Type of Center: 1 (Center at which patients were screened) or 2 (Center initiated at which patients were never screened) Study Center No. Local and/or National IRB/IEC Name and Address ------------------- Type of Center: 1 (Center at which patients were screened) ARGENTINA (Local IRBs/IECs only) 0320001 CIE para Ensayos en Farmacologia Clin Prof Dr Luis M. Zieher Jose E. Uriburu 774 piso 1 C1027AAP Buenos Aires 0320003 Comite de Etica e Investigacion Fundacion Sanatorio Guemes Acuna de Figueroa 1240 C1180AAX, CABA Buenos Aires 0320004 Clinica y Maternidad Suizo Argentina Av. Pueyrredon 1461 C1414CED,CABA Buenos Aires BRAZIL (Local IRB/IEC only) 0760001 Hospital Alemao Oswaldo Cruz Rua 13 de Maio, 1815 1. subsolo - bloco A Sao Paulo 01327-001 0760002 Ethics Committee of Hospital Heliopolis Rua Conego Xavier, 276 10o andar Bairro Sacoma Sao Paulo 04231-030 0760003 EC of Associacao Educadora Sao Carlos - H. Mae de Deus Rua Grao Para, no. 160, 2. andar - Bairro Menino Deus Porto Alegre 90850-170 Rio Grande do Sul 0760004 EC of Faculdade de Medicina de Sao Jose do Rio Preto Av. Brigadeiro Faria Lima, 5416 Vila Sao Pedro Sao Jose Do Rio Preto 15090-000 0760005 EC of REDE D'OR SAO LUIZ S.A. Rua Dr. Alceu de Campos Rodrigues, 95 - Vila Nova Conceicao Sao Paulo 04544-000 CANADA (Local IRB/IEC only) 1240001 Comite d'ethique de la recherche du CHUM 900 rue St-Denis, Pavillon R, R03.456 Montreal H2X 0A9 Quebec 1240002 University Health Network IRB 700 University Avenue 10th Floor North, Room 1056 Toronto M5G 1Z5 Ontario 1240003 The University of British Columbia Office of Research Ethics Clinical Research Ethics Board Room 210, 828 West 10th Avenue Vancouver V5Z 1L8 British Columbia 1240004 Sunnybrook Health Sciences Centre Research Ethics Office, Room C819 2075 Bayview Avenue Toronto M4N 3M5 Ontario 1240005 Comite d'ethique de la recherche du CHUM 900 rue St-Denis, Pavillon R, R03. 456 Montreal, H2X 0A9 Quebec CHILE (Local IRB/IEC only) 1520001 Comite de Etica Cientifico S.S. M Oriente Av . Salvador # 364 Providencia Santiago 7500922 Reg Metropolitana de Santiago 1520002 Comite de Etica de la Investigacion S.S.M Central Victoria subercaseaux 381, 5. piso, Santiago Centro Santiago 8360160 Reg Metropolitana de Santiago 1520003 Comite de Etica Cientifico S.S. M Oriente Av . Salvador # 364 Providencia Santiago 7500922 Reg Metropolitana de Santiago 1520004 Comite de Etica Cientifico S.S. M Sur Oriente Avda. Concha y Toro 3459, Puente Alto Santiago Reg Metropolitana de Santiago FRANCE (National IRB/IEC only) 2500001 2500002 2500003 2500004 2500005 2500006 2500007 Comite de Protection de Personnes IDF 1 Hotel-Dieu 1, Place du Parvis Notre-Dame 75181 Paris Cedex 04 GERMANY (Local and Regional IRB/IEC) 2760001 Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Medizinischen Fakultaet der Westfaelischen Wilhelms-Universitaet Muenster Gartenstrasse 210-214 Muenster 48147 Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Medizinischen Fakultaet der Westfaelischen Wilhelms-Universitaet Muenster Gartenstrasse 210-214 Muenster 48147 2760002 Ethik- Kommission der Medizinischen Fakultaet der Universitaet Duisburg- Essen Robert-Koch-Str. 9-11 Essen 45147 Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Medizinischen Fakultaet der Westfaelischen Wilhelms-Universitaet Muenster Gartenstrasse 210-214 Muenster 48147 2760004 Ethikkommission der Medizinischen Fakultaet der Universitaet zu Koeln Kerpener Str. 62 Koeln 50937 Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Medizinischen Fakultaet der Westfaelischen Wilhelms-Universitaet Muenster Gartenstrasse 210-214 Muenster 48147 ISRAEL (Local IRB/IEC only) 3760001 Helsinki committee Chaim Sheba Medical Center 2 Sheba Rd. Tel Hashomer Ramat gan 52662 3760002 Helsinki committee Hadassah Ein Kerem MC Ein Kerem, POB 12221, Jerusalem, 91120 ITALY (National IRB/IEC only) 3800001 3800002 3800003 3800004 3800005 3800006 CE dell'Istituto Nazionale per le Malattie infettive "L. Spallanzani" IRCCS Via portuense 292, 00149 Roma JAPAN (Local IRB/IEC only) 3920001 Institutional Review Board of Shonan Kamakura Hospital 1370-1 Okamoto Kamakura-Shi 247-0072 Kanagawa 3920002 IRB of Tokyo Metroporitan Tama Medical Center( #1) 2-8-29 Musashidai Fuchu-shi 183-8524 JP-13 RUSSIAN FEDERATION (Local and national IRB/IEC) 6430001 Moscow City Independent Ethics Committee 12, build.2, Minskaya str., Moscow 121096 Ethics Board at Ministry of Health of the Russian Federation 3, Rakhmanovskiy per., Moscow 127994 6430002 Local Ethics Committee of the City Clinical Hospital #52 3, Pekhotnaya st. Moscow 123182 Ethics Board at Ministry of Health of the Russian Federation 3, Rakhmanovskiy per., Moscow 127994 6430003 Moscow City Independent Ethics Committee 12, build.2, Minskaya str., Moscow 121096 Ethics Board at Ministry of Health of the Russian Federation 3, Rakhmanovskiy per., Moscow 127994 SPAIN (National IRB/IEC only) 7240001 7240002 7240003 7240004 7240005 Comite Etico de Investigacion con medicamentos (CEIm) Hospital General Universitario Gregorio Maranon C/ Doctor Esquerdo, 46 28007 Madrid ------------------- Type of Center: 2 (Center initiated at which patients were never screened) GERMANY (National IRB/IEC Only) 2760003 2760006 Ethik-Kommission der Aerztekammer Westfalen-Lippe und der Medizinischen Fakultaet der Westfaelischen Wilhelms-Universitaet Muenster Gartenstrasse 210-214 Muenster 48147 ISRAEL (Local IRB/IEC only) 3760003 Helsinki committee Samson Assuta Ashdod University Hospital. Ha-Refu'a St 7, Ashdod, 7747629 JAPAN (Local IRB/IEC only) 3920003 IRB of Saitama Medical University Hospital( #1) 38 Morohongo, Moroyama-machi Iruma-gun 350-0495 JP-11
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Qualified researchers may request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and data set specifications. Patient-level data will be anonymised and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data-sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com
